R&D expense · 2015–2025
AstraZeneca R&D expense
$14.2B+4.8% · FY2025
AstraZeneca (AZN) reported $14.2B in R&D expense for fiscal 2025, +4.8% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $14.2B | +4.8% | Open → |
| FY20242024-12-31 | $13.6B | +24.2% | Open → |
| FY20232023-12-31 | $10.9B | +12.0% | Open → |
| FY20222022-12-31 | $9.8B | +0.3% | Open → |
| FY20212021-12-31 | $9.7B | +62.5% | Open → |
| FY20202020-12-31 | $6.0B | −1.1% | Open → |
| FY20192019-12-31 | $6.1B | +2.1% | Open → |
| FY20182018-12-31 | $5.9B | +3.0% | Open → |
| FY20172017-12-31 | $5.8B | −2.3% | Open → |
| FY20162016-12-31 | $5.9B | −1.8% | Open → |
| FY20152015-12-31 | $6.0B | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2015–2025 compound annual growth +9.0%
Figures are reported under IFRS, in US dollars.
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=AstraZeneca R&D expense |url=https://companiesranked.com/en/company/astrazeneca/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). AstraZeneca R&D expense. CompaniesRanked. https://companiesranked.com/en/company/astrazeneca/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-astrazeneca-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{AstraZeneca R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/astrazeneca/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 20-F · 0001104659-26-019130 · February 24, 2026
{{cite web |title=AstraZeneca R&D expense — 20-F (0001104659-26-019130) |url=https://www.sec.gov/Archives/edgar/data/901832/000110465926019130/azn-20251231x20f.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-24}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.